

Publikationen 2004

Arning L, Jagiello P, Schara U, Vorgerd M, **Dahmen N**, Gencikova A, Mortier W, Epplen JT, Gencik M (2004) Transcriptional profiles from patients with determined by qRT-PCR. *J Neurol* 251: 72-78

Baumann P, **Hiemke C**, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G (2004) The AGNP-TDM expert group consensus guidelines: therapeutic monitoring of psychotropic drugs. *Pharmacopsychiatry* 37: 243-265

Baumann P, **Hiemke C**, Ulrich S, Gaertner I, Rao ML, Eckermann G, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, Riederer P, Zernig G (2004) Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. *Ther Drug Monit* 26: 167-170

Böhme I, Rabe H, Lüddens H (2004) Four amino acids in the alpha subunits determine the gamma-aminobutyric acid sensitivities of GABA_A receptor subtypes. *J Biol Chem* 279: 35193-35200

Degner D, Grohmann R, Kropp S, Rüter E, Bender S, Engel RR, **Schmidt LG** (2004) Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. *Pharmacopsychiatry* 37, Suppl 1: S39-45

El Ela AA, **Härter S, Schmitt U, Hiemke C**, Spahn-Langguth H, Langguth P (2004) Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. *J Pharm Pharmacol* 56: 967-975

Fehr C, Shirley RL, Metten P, Kosobud AE, Belknap JK, Crabbe JC, Buck KJ (2004) Potential pleiotropic effects of Mpdz on vulnerability to seizures. *Genes Brain Behav* 3: 8-19

Fellgiebel A, Siessmeier T, **Scheurich A, Winterer G**, Bartenstein P, **Schmidt LG, Müller MJ** (2004) Association of elevated phospho-tau levels with alzheimer-typical 18F-Fluoro-2-Deoxy-D-Glucose positron emission tomography findings in patients with mild cognitive impairment. *Biol Psychiatry* 56: 279-283

Fellgiebel A, Siessmeier T, **Winterer G, Lüddens H, Mann K, Schmidt LG**, Bartenstein P (2004) Increased cerebellar pet glucose metabolism corresponds to ataxia in wernicke-korsakoff syndrome. *Alcohol Alcohol* 39: 150-153

Fellgiebel A, Wille P, **Müller MJ, Winterer G, Scheurich A**, Vucurevic G, **Schmidt LG**, Stoeter P (2004) Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: a diffusion tensor imaging study. *Dement Geriatr Cogn Disord* 18: 101-108

Gallinat J, **Winterer G**, Herrmann CS, Senkowski D (2004) Reduced oscillatory gamma-band responses in unmedicated schizophrenic patients indicate impaired frontal network processing. *Clin Neurophysiol* 115: 1863-1874

Grasmäder K, Verwohlt PL, Kühn KU, **Dragicevic A**, von Widdern O, Zobel A, **Hiemke C**, Rietschel M, Maier W, Jaehde U, Rao ML (2004) Population pharmacokinetic analysis of mirtazapine. *Eur J Clin Pharmacol* 60: 473-480

Grasmäder K, Verwohlt PL, Rietschel M, **Dragicevic A**, **Müller M**, **Hiemke C**, Freymann N, Zobel A, Maier W, Rao ML (2004) Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. *Eur J Clin Pharmacol*: *Eur J Clin Pharmacol* 60: 329-336

Grohmann R, Hippus H, Helmchen H, Rütther E, **Schmidt LG** (2004) The AMÜP study for drug surveillance in psychiatry - a summary of inpatient data. *Pharmacopsychiatry* 37 Suppl 1: S16-26

Härter S, Connemann B, Schonfeldt-Lecuona C, **Sachse J**, **Hiemke C** (2004) Elevated quetiapine serum concentrations in a patient treated concomitantly with doxepin, lorazepam, and pantoprazole. *J Clin Psychopharmacol* 24: 568-571

Heinz A, Siessmeier T, Wrase J, Hermann D, Klein S, Grüsser SM, Flor H, Braus DF, Buchholz HG, **Gründer G**, Schreckenberger M, Smolka MN, Rösch F, Mann K, Bartenstein P (2004) Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. *Am J Psychiatry* 161: 1783-1789

Heller S, **Hiemke C**, **Stroba G**, **Rieger-Gies A**, **Daum-Kreysch E**, **Sachse J**, **Härter S** (2004) Assessment of Storage and Transport Stability of New Antidepressant and Antipsychotic Drugs for a Nationwide TDM Service. *Ther Drug Monit* 26: 459-461

Hiemke C (2004) Optimierung der Psychopharmakotherapie mit therapeutischem Drug Monitoring. In: Rütther E (hrsg) 7. Bad Homburger ZNS-Gespräche. Springer, Heidelberg. S. 10-11

Hiemke C (2004) Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika. *J Lab Med* 28: 326-333

Hiemke C, **Dragicevic A** (2004) Die Wertigkeit von Plasmaspiegelbestimmung in der Psychiatrie. *Info Neurologie & Psychiatrie* 6: 34-39

Hiemke C, **Dragicevic A**, **Gründer G**, **Härter S**, **Sachse J**, **Vernaleken I**, **Müller MJ** (2004) Therapeutic monitoring of new antipsychotic drugs. *Ther Drug Monit* 26: 156-160

Himmerich H, **Müller MJ**, Angheltescu I, **Klawe C**, **Scheurich A**, Szegedi A (2004) Antisocial Personality Disorder and its Correlate in the Michigan Alcoholism Screening Test. *German J Psychiatry* 7: 14-19

Mann K, **Röschke J** (2004) Influence of age on the interrelation between EEG frequency bands during NREM and REM sleep. *Int J Neurosci* 114: 559-571

Mann K, **Röschke J** (2004) Sleep under exposure to high-frequency electromagnetic fields. *Sleep Med Rev* 8: 95-107

Mann K, Rossbach W, Müller MJ, Müller-Siecheneder F, Ruß H, Dittmann RW (2004) Heart rate variability during sleep in patients with schizophrenia treated with olanzapine. *Int Clin Psychopharmacol* 19: 325-330

Müller MJ (2004) Therapy of erectile dysfunction (ED) with sildenafil improves quality of life (QoL) and partnership (QoP). In: Dunzendorfer U (ed.) *Sildenafil*. Birkhäuser, Basel. pp 83-100

Müller MJ (2004) Vorteile und Risiken einer antidepressiven Zusatzmedikation bei schizophrenen Psychosen. *Neurodate* 18: 12-18

Müller MJ, Rossbach W, Mann K, Röschke J, Müller-Siecheneder F, Blümner M, Wetzel H, Russ H, Dittmann RW, Benkert O (2004) Subchronic effects of olanzapine on sleep EEG in schizophrenic patients with predominantly negative symptoms. *Pharmacopsychiatry* 37: 157-162

Postina R, Schroeder A, Dewachter I, Bohl J, **Schmitt U**, Kojro E, Prinzen C, Endres K, **Hiemke C**, Blessing M, Flamez P, Dequenne A, Godaux E, van Leuven F, Fahrenholz F (2004) A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. *J Clin Invest* 113: 1384-1387

Schanz, B (2004) Fixierung und Überwachung von fixierten Patienten. *Psych Pflege* 10: 138-143

Scheurich A, Müller MJ, Szegedi A, Angheliescu I, Klawe C, Lörch B, Kappis B, Bialonski HG, Haas S, Hautzinger M (2004) Neuropsychological status of alcohol-dependent patients: increased performance through goal-setting instructions. *Alcohol Alcohol* 39: 119-125

Schmidt LG (2004) Die besten Argumente für den Ausstieg aus der Tabaksucht: Motivator Hausarzt. *MMW-Fortschr Med* 146 (17): 34, 36, 38-39

Schneider B, **Weigmann H, Hiemke C**, Weber B, Fritze J (2004) Reduction of clozapine-induced hypersalivation by pirenzepine is safe. *Pharmacopsychiatry* 37: 43-45

Schreckenberger M, Amberg R, **Scheurich A**, Lochmann M, Tichy W, Klega A, Siessmeier T, **Gründer G**, Buchholz HG, Landvogt C, Stauss J, **Mann K**, Bartenstein P, Urban R (2004) Acute alcohol effects on neuronal and attentional processing: striatal reward system and inhibitory sensory interactions under acute ethanol challenge. *Neuropsychopharmacology* 29: 1527-1537

Schreckenberger M, Hägele S, Siessmeier T, Buchholz HG, Armbrust-Henrich H, Rösch F, **Gründer G**, Bartenstein P, Vogt T (2004) The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. *Eur J Nucl Med Mol Imaging* 31: 1128-1135

Schreckenberger M, **Lange-Asschenfeld C**, Lochmann M, **Mann K**, Siessmeier T, Buchholz HG, Bartenstein P, **Gründer G** (2004) The thalamus as the generator and modulator of EEG alpha rhythm: a combined PET/EEG study with lorazepam challenge in humans. *Neuroimage* 22: 637-644

Shams M, **Hiemke C, Härtter S** (2004) Therapeutic drug monitoring of the antidepressant mirtazapine and its N-demethylated metabolite in human serum. *Ther Drug Monit* 26: 78-84

Shirley RL, Walter NA, Reilly MT, **Fehr C**, Buck KJ (2004) Mpdz is a quantitative trait gene for drug withdrawal seizures. *Nat Neurosci* 7: 699-700

Sinkkonen ST, Lüscher B, **Lüddens H**, Korpi ER (2004) Autoradiographic imaging of altered synaptic α_2 and extrasynaptic α_1 GABA_A receptors in a genetic mouse model of anxiety. *Neurochem Int* 44: 539-547

Smolka MN, Budde H, Karow AC, **Schmidt LG** (2004) Neuroendocrinological and neuropsychological correlates of dopaminergic function in nicotine dependence. *Psychopharmacology (Berl)* 175: 374-381

Tonn P, Reuter S, Treder B, Dahmen N (2004) Die präklinische Behandlung von akut erregten, deliranten oder psychotischen Patienten durch den Notarzt. *Notfall & Rettungsmedizin* 7: 484-492

Vernaleken I, Siessmeier T, Buchholz HG, **Härtter S, Hiemke C**, Stoeter P, Rösch F, Bartenstein P, **Gründer G** (2004) High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. *Int J Neuropsychopharmacol* 7: 421-430

Wetzel H, Szegedi A, **Scheurich A, Lörch B, Singer P**, Schläfke D, Sittinger H, Wobrock T, **Müller MJ**, Anghelescu I, Hautzinger M; NeVeR Study Group (2004) Combination treatment with nefazodone and cognitive-behavioral therapy for relapse prevention in alcohol-dependent men: a randomized controlled study. *J Clin Psychiatry* 65: 1406-1413

Wieczorek S, **Dahmen N, Kasten M**, Epplen JT, Gencik M (2004) A rare form of narcolepsy (HLA-DR2-) shows possible association with (functionally relevant) alpha-interferon gene polymorphisms. *Psychiatr Genet* 14: 47-51

Wieczorek S, Jagiello P, Arning L, **Dahmen N**, Epplen JT (2004) Screening for candidate gene regions in narcolepsy using a microsatellite based approach and pooled DNA. *J Mol Med* 82: 696-705

Winterer G, Coppola R, Goldberg TE, Egan MF, Jones DW, Sanchez CE, Weinberger DR (2004) Prefrontal broadband noise, working memory, and genetic risk for schizophrenia. *Am J Psychiatry* 161: 490-500

Winterer G, Schmitt U, Schmidt LG (2004) Reply: Valproate Treatment in Schizophrenia: Interaction of GABA with Dopamine? *Neuropsychopharmacology* 29: 1218-1220

Winterer G, Weinberger DR (2004) Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. *Trends Neurosci* 27: 683-690

Zernig G, Lechner T, Kramer-Reinstadler K, Hinterhuber H, **Hiemke C**, Saria A (2004) What the clinician still has to be reminded of. *Ther Drug Monit* 26: 582